Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PolarisDMD: Edasalonexent in Pediatric DMD
NCT03703882Phase 3Completed
- Sponsor
- Astria Therapeutics
- Start
- Oct 2018
- Primary completion
- Sep 2020
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in Duchenne muscular dystrophy (DMD) comparing Edasalonexent with Placebo (2 arms). Primary endpoint: North Star Ambulatory Assessment at 52 weeks. Started Oct 2018; status: completed.
02
Drugs
edasalonexent
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT03703882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03703882.